| 000 | 01836 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250511184632.0 | ||
| 264 | 0 | _c19930107 | |
| 008 | 199301s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1992.10.12.1907 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFoss, F M | |
| 245 | 0 | 0 |
_aPhase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cDec 1992 |
||
| 300 |
_a1907-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycosis Fungoides _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPentostatin _xadministration & dosage |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aSezary Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aIhde, D C | |
| 700 | 1 | _aBreneman, D L | |
| 700 | 1 | _aPhelps, R M | |
| 700 | 1 | _aFischmann, A B | |
| 700 | 1 | _aSchechter, G P | |
| 700 | 1 | _aLinnoila, I | |
| 700 | 1 | _aBreneman, J C | |
| 700 | 1 | _aCotelingam, J D | |
| 700 | 1 | _aGhosh, B C | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 10 _gno. 12 _gp. 1907-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1992.10.12.1907 _zAvailable from publisher's website |
| 999 |
_c1459696 _d1459696 |
||